CoChat

Microglial ERK-NRBP1-CREB-BDNF signaling in sustained antidepressant actions of (R)-ketamine

Open access

The DOI matches its Crossref record; 80 of the 80 references it cites were found in a registry or an index.

Abstract

(R,S)-ketamine elicits rapid-acting and sustained antidepressant actions in treatment-resistant patients with depression. (R)-ketamine produces longer-lasting antidepressant effects than (S)-ketamine in rodents; however, the precise molecular mechanisms underlying antidepressant actions of (R)-ketamine remain unknown. Using isobaric Tag for Relative and Absolute Quantification, we identified nuclear receptor-binding protein 1 (NRBP1) that could contribute to different antidepressant-like effects of the two enantiomers in chronic social defeat stress (CSDS) model. NRBP1 was localized in the microglia and neuron, not astrocyte, of mouse medial prefrontal cortex (mPFC). (R)-ketamine increased the expression of NRBP1, brain-derived neurotrophic factor (BDNF), and phosphorylated cAMP response element binding protein (p-CREB)/CREB ratio in primary microglia cultures thorough the extracellular signal-regulated kinase (ERK) activation. Furthermore, (R)-ketamine could activate BDNF transcription through activation of CREB as well as MeCP2 (methyl-CpG binding protein 2) suppression in microglia. Single intracerebroventricular (i.c.v.) injection of CREB-DNA/RNA heteroduplex oligonucleotides (CREB-HDO) or BDNF exon IV-HDO blocked the antidepressant-like effects of (R)-ketamine in CSDS susceptible mice. Moreover, microglial depletion by colony-stimulating factor 1 receptor (CSF1R) inhibitor PLX3397 blocked the antidepressant-like effects of (R)-ketamine in CSDS susceptible mice. In addition, inhibition of microglia by single i.c.v. injection of mannosylated clodronate liposomes (MCLs) significantly blocked the antidepressant-like effects of (R)-ketamine in CSDS susceptible mice. Finally, single i.c.v. injection of CREB-HDO, BDNF exon IV-HDO or MCLs blocked the beneficial effects of (R)-ketamine on the reduced dendritic spine density in the mPFC of CSDS susceptible mice. These data suggest a novel ERK-NRBP1-CREB-BDNF pathways in microglia underlying antidepressant-like effects of (R)-ketamine.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41380-021-01377-7

Cites

80 of 80 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Effects of (R)-ketamine and (S)-ketamine on the BDNF activation. A, B The luciferase assay for BDNF exon IV promoter. A BDNF exon IV promoter activity in the HEK293T cells treated with (R)-ketamine (0.1, 1.0, and 10 μM) or (S)-ketamine (0.1, 1.0, and 10 μM). The data are the mean ± SEM (n = 6). **P < 0.01; ***P < 0.001 compared to vehicle group. $P < 0.05; $$P < 0.01; $$$P < 0.001 (one-way ANOVA). B BDNF exon IV promoter activity in the HEK293T cells treated with (R)-ketamine (10 μM) [or (S)-ketamine (10 μM)] with or without mutation (Mut) plasmids. The data are the mean ± SEM (n = 9 or 10). **P < 0.01; ***P < 0.001 (one-way ANOVA). C BDNF exon IV promoter activity in the HEK293T cells treated with (R)-ketamine (10 μM) with or without siRNA-CREB plasmids. The data are the mean ± SEM (n = 4). **P < 0.01; ***P < 0.001 (one-way ANOVA). D BDNF exon IV promoter activity in the HEK293T cells treated with (R)-ketamine (10 μM) with or without CREB-HDO or BDNF exon IV-HDO. The data are the mean ± SEM (n = 10). **P < 0.01; ***P < 0.001 (one-way ANOVA). E ChIP-PCR assay for BDNF IV promoter. The p-CREB protein–DNA crosslinking samples were obtained from the primary microglia treated with vehicle, (R)-ketamine (10 μM), or (S)-ketamine (10 μM) via co-immunoprecipitating with anti-p-CREB. PCR was carried out by using BDNF exon IV promoter primer. The data are the mean ± SEM (n = 4). *P < 0.05; ***P < 0.001 (one-way ANOVA). F The immunofluorescence for p-CREB and MeCP2 in the LPS (1 µg/mL)-treated primary microglia with (R)-ketamine (10 µM) or (S)-ketamine (10 µM). Scale bar = 50 μm. G Expression of NRBP1, BDNF, MeCP2, and the ratio of p-CREB/CREB in the LPS-treated primary microglia with (R)-ketamine (10 µM) or (S)-ketamine (10 µM). The data are the mean ± SEM (n = 5). *P < 0.05; **P < 0.01; ***P < 0.001 (one-way ANOVA).
Fig. 1 Effects of (R)-ketamine and (S)-ketamine on the BDNF activation. A, B The luciferase assay for BDNF exon IV promoter. A BDNF exon IV promoter activity in the HEK293T cells treated with (R)-ketamine (0.1, 1.0, and 10 μM) or (S)-ketamine (0.1, 1.0, and 10 μM). The data are the mean ± SEM (n = 6). **P < 0.01; ***P < 0.001 compared to vehicle group. $P < 0.05; $$P < 0.01; $$$P < 0.001 (one-way ANOVA). B BDNF exon IV promoter activity in the HEK293T cells treated with (R)-ketamine (10 μM) [or (S)-ketamine (10 μM)] with or without mutation (Mut) plasmids. The data are the mean ± SEM (n = 9 or 10). **P < 0.01; ***P < 0.001 (one-way ANOVA). C BDNF exon IV promoter activity in the HEK293T cells treated with (R)-ketamine (10 μM) with or without siRNA-CREB plasmids. The data are the mean ± SEM (n = 4). **P < 0.01; ***P < 0.001 (one-way ANOVA). D BDNF exon IV promoter activity in the HEK293T cells treated with (R)-ketamine (10 μM) with or without CREB-HDO or BDNF exon IV-HDO. The data are the mean ± SEM (n = 10). **P < 0.01; ***P < 0.001 (one-way ANOVA). E ChIP-PCR assay for BDNF IV promoter. The p-CREB protein–DNA crosslinking samples were obtained from the primary microglia treated with vehicle, (R)-ketamine (10 μM), or (S)-ketamine (10 μM) via co-immunoprecipitating with anti-p-CREB. PCR was carried out by using BDNF exon IV promoter primer. The data are the mean ± SEM (n = 4). *P < 0.05; ***P < 0.001 (one-way ANOVA). F The immunofluorescence for p-CREB and MeCP2 in the LPS (1 µg/mL)-treated primary microglia with (R)-ketamine (10 µM) or (S)-ketamine (10 µM). Scale bar = 50 μm. G Expression of NRBP1, BDNF, MeCP2, and the ratio of p-CREB/CREB in the LPS-treated primary microglia with (R)-ketamine (10 µM) or (S)-ketamine (10 µM). The data are the mean ± SEM (n = 5). *P < 0.05; **P < 0.01; ***P < 0.001 (one-way ANOVA).CC BY · PubMed Central
Fig. 2 Effects of CREB-HDO on beneficial effects of (R)-ketamine on depression-like behaviors, and expression of p-CREB, CREB, BDNF, MeCP2, and CD11b in the mPFC. A Schematic illustration of the construction of ASO, cRAN, and HDO. B Graphical illustration of intracerebroventricular (i.c.v.) injection site and the distribution of CY5-CREB-HDO in the brain. C The schedule of CSDS, treatment, behavioral tests, and sample collection. CSDS was performed from day 1 to day 10. On day 11, social interaction test (SIT) was performed to select CSDS susceptible mice. CREB-HDO or vehicle was injected i.c.v. to mice 30 min before i.p. injection of (R)-ketamine (10 mg/kg). Subsequently, behavioral tests such as locomotion tests (LMT), forced swimming test (FST), and sucrose preference test (SPT) were performed. D LMT. E FST. F SPT. The data are the mean ± SEM (n = 7 or 8). *P < 0.05; **P < 0.01; ***P < 0.001 (one-way ANOVA). G The expression of p-CREB, CREB, BDNF, and MeCP2 in the mPFC. The data are the mean ± SEM (n = 5). *P < 0.05; **P < 0.01; ***P < 0.001 (one-way ANOVA). H The immunofluorescence analysis for p-CREB and CD11b in the mPFC. The data are the mean ± SEM (n = 5). **P < 0.01; ***P < 0.001 (one-way ANOVA). Scale bar = 50 μm.
Fig. 2 Effects of CREB-HDO on beneficial effects of (R)-ketamine on depression-like behaviors, and expression of p-CREB, CREB, BDNF, MeCP2, and CD11b in the mPFC. A Schematic illustration of the construction of ASO, cRAN, and HDO. B Graphical illustration of intracerebroventricular (i.c.v.) injection site and the distribution of CY5-CREB-HDO in the brain. C The schedule of CSDS, treatment, behavioral tests, and sample collection. CSDS was performed from day 1 to day 10. On day 11, social interaction test (SIT) was performed to select CSDS susceptible mice. CREB-HDO or vehicle was injected i.c.v. to mice 30 min before i.p. injection of (R)-ketamine (10 mg/kg). Subsequently, behavioral tests such as locomotion tests (LMT), forced swimming test (FST), and sucrose preference test (SPT) were performed. D LMT. E FST. F SPT. The data are the mean ± SEM (n = 7 or 8). *P < 0.05; **P < 0.01; ***P < 0.001 (one-way ANOVA). G The expression of p-CREB, CREB, BDNF, and MeCP2 in the mPFC. The data are the mean ± SEM (n = 5). *P < 0.05; **P < 0.01; ***P < 0.001 (one-way ANOVA). H The immunofluorescence analysis for p-CREB and CD11b in the mPFC. The data are the mean ± SEM (n = 5). **P < 0.01; ***P < 0.001 (one-way ANOVA). Scale bar = 50 μm.CC BY · PubMed Central
Fig. 3 Effects of BDNF exon IV-HDO on antidepressant-like effects of (R)-ketamine. A Graphical illustration of BDNF exon IV-HDO to inhibit BDNF exon IV promoter expression. B, C qPCR and western blot assay for BDNF exon IV promoter and BDNF protein expression in the BV2 cells after administration of BDNF exon IV-HDO. The data are the mean ± SEM (n = 5). *P < 0.05; **P < 0.01 (one-way ANOVA). D Expression of BDNF in the mPFC of adult mice 72 h after i.c.v. administration of BDNF exon IV-HDO. The data are the mean ± SEM (n = 4). *P < 0.05 (Student t test). E The schedule of CSDS, treatment, behavioral tests, and sample collection. CSDS was performed from day 1 to day 10. On day 11, SIT was performed to select CSDS susceptible mice. BDNF exon IV-HDO or vehicle was injected i.c.v. to mice 30 min before i.p. injection of (R)-ketamine (10 mg/kg). Subsequently, behavioral tests such as LMT, FST, and SPT were performed. F LMT. G FST. H SPT. The data are the mean ± SEM (n = 9). *P < 0.05; **P < 0.01; ***P < 0.001 (one-way ANOVA). I Expression of BDNF in the mPFC. The data are the mean ± SEM (n = 5). **P < 0.01 (one-way ANOVA). J The immunofluorescence analysis for CD11b (for microglia) in the mPFC. The data are the mean ± SEM (n = 5). *P < 0.05; **P < 0.01 (one-way ANOVA). Scale bar = 50 μm.
Fig. 3 Effects of BDNF exon IV-HDO on antidepressant-like effects of (R)-ketamine. A Graphical illustration of BDNF exon IV-HDO to inhibit BDNF exon IV promoter expression. B, C qPCR and western blot assay for BDNF exon IV promoter and BDNF protein expression in the BV2 cells after administration of BDNF exon IV-HDO. The data are the mean ± SEM (n = 5). *P < 0.05; **P < 0.01 (one-way ANOVA). D Expression of BDNF in the mPFC of adult mice 72 h after i.c.v. administration of BDNF exon IV-HDO. The data are the mean ± SEM (n = 4). *P < 0.05 (Student t test). E The schedule of CSDS, treatment, behavioral tests, and sample collection. CSDS was performed from day 1 to day 10. On day 11, SIT was performed to select CSDS susceptible mice. BDNF exon IV-HDO or vehicle was injected i.c.v. to mice 30 min before i.p. injection of (R)-ketamine (10 mg/kg). Subsequently, behavioral tests such as LMT, FST, and SPT were performed. F LMT. G FST. H SPT. The data are the mean ± SEM (n = 9). *P < 0.05; **P < 0.01; ***P < 0.001 (one-way ANOVA). I Expression of BDNF in the mPFC. The data are the mean ± SEM (n = 5). **P < 0.01 (one-way ANOVA). J The immunofluorescence analysis for CD11b (for microglia) in the mPFC. The data are the mean ± SEM (n = 5). *P < 0.05; **P < 0.01 (one-way ANOVA). Scale bar = 50 μm.CC BY · PubMed Central
Fig. 4 Effects of PLX3397 and MCLs on the antidepressant-like effects of (R)-ketamine in the CSDS susceptible mice. A The schedule of treatment, behavioral tests, and collection of samples. CSDS was performed from day 1 to day 10. On day 11, SIT was performed to select CSDS susceptible mice. On day 12, PLX3397 or vehicle was injected i.c.v. to CSDS susceptible mice. (R)-ketamine (10 mg/kg) or saline was administered i.p. 24 h after PLX injection. Subsequently, behavioral tests such as LMT, FST, and SPT were performed. B The schedule of treatment, behavioral tests, and collection of samples. CSDS was performed from day 1 to day 10. On day 11, SIT was performed to select CSDS susceptible mice. On day 12, MCLs or vehicle was injected i.c.v. to CSDS susceptible mice 30 min before i.p. injection of (R)-ketamine (10 mg/kg) or saline (10 ml/kg). Subsequently, behavioral tests such as LMT, FST, and SPT were performed. C, F: LMT. D, G: FST. E, H: SPT. The data are the mean ± SEM (n = 7 or 8). *P < 0.05; **P < 0.01 (one-way ANOVA). I The ratio of p-CREB/CREB, expression of BDNF, and MeCP2 in the mPFC. The data are the mean ± SEM (n = 5). *P < 0.05; ***P < 0.001 (one-way ANOVA). J The immunofluorescence analysis for arginase1 and p-CREB in the mPFC. The data are the mean ± SEM (n = 5). **P < 0.01; ***P < 0.001 (one-way ANOVA). Scale bar = 50 μm.
Fig. 4 Effects of PLX3397 and MCLs on the antidepressant-like effects of (R)-ketamine in the CSDS susceptible mice. A The schedule of treatment, behavioral tests, and collection of samples. CSDS was performed from day 1 to day 10. On day 11, SIT was performed to select CSDS susceptible mice. On day 12, PLX3397 or vehicle was injected i.c.v. to CSDS susceptible mice. (R)-ketamine (10 mg/kg) or saline was administered i.p. 24 h after PLX injection. Subsequently, behavioral tests such as LMT, FST, and SPT were performed. B The schedule of treatment, behavioral tests, and collection of samples. CSDS was performed from day 1 to day 10. On day 11, SIT was performed to select CSDS susceptible mice. On day 12, MCLs or vehicle was injected i.c.v. to CSDS susceptible mice 30 min before i.p. injection of (R)-ketamine (10 mg/kg) or saline (10 ml/kg). Subsequently, behavioral tests such as LMT, FST, and SPT were performed. C, F: LMT. D, G: FST. E, H: SPT. The data are the mean ± SEM (n = 7 or 8). *P < 0.05; **P < 0.01 (one-way ANOVA). I The ratio of p-CREB/CREB, expression of BDNF, and MeCP2 in the mPFC. The data are the mean ± SEM (n = 5). *P < 0.05; ***P < 0.001 (one-way ANOVA). J The immunofluorescence analysis for arginase1 and p-CREB in the mPFC. The data are the mean ± SEM (n = 5). **P < 0.01; ***P < 0.001 (one-way ANOVA). Scale bar = 50 μm.CC BY · PubMed Central
Fig. 5 Effects of CREB-HDO, BDNF exon IV-HDO, or MCLs on beneficial effects of (R)-ketamine for reduced dendritic spine density in the mPFC of CSDS susceptible mice. A The schedule of CSDS, treatment, and collection of samples. CSDS of Thy1-YFP mice was performed from day 1 to day 10. On day 11, SIT was performed to select CSDS susceptible mice. On day 12, HDO, MCLs or vehicle was injected i.c.v. to CSDS susceptible mice 30 min before i.p. injection of (R)-ketamine (10 mg/kg) or saline (10 ml/kg). On day 15, brain samples were collected. B The representative photomicrographs for dendritic spine density in the mPFC. Scale bar = 10 μm. C The quantification analysis of dendritic spine density in the mPFC. The data are the mean ± SEM (n = 5). ***P < 0.001 (one-way ANOVA). D Working model for the longer-lasting antidepressant-like effects of (R)-ketamine. (R)-ketamine produces long-lasting antidepressant-like effects through microglial NRBP1-CREB-MeCP2-BDNF signaling in the mPFC.
Fig. 5 Effects of CREB-HDO, BDNF exon IV-HDO, or MCLs on beneficial effects of (R)-ketamine for reduced dendritic spine density in the mPFC of CSDS susceptible mice. A The schedule of CSDS, treatment, and collection of samples. CSDS of Thy1-YFP mice was performed from day 1 to day 10. On day 11, SIT was performed to select CSDS susceptible mice. On day 12, HDO, MCLs or vehicle was injected i.c.v. to CSDS susceptible mice 30 min before i.p. injection of (R)-ketamine (10 mg/kg) or saline (10 ml/kg). On day 15, brain samples were collected. B The representative photomicrographs for dendritic spine density in the mPFC. Scale bar = 10 μm. C The quantification analysis of dendritic spine density in the mPFC. The data are the mean ± SEM (n = 5). ***P < 0.001 (one-way ANOVA). D Working model for the longer-lasting antidepressant-like effects of (R)-ketamine. (R)-ketamine produces long-lasting antidepressant-like effects through microglial NRBP1-CREB-MeCP2-BDNF signaling in the mPFC.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

4 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 80 references

Cited by

See all 216

Metadata

Authors
Yao, W., Cao, Q., Luo, S., He, L., Yang, C., Chen, J., Qi, Q., Hashimoto, K., & Zhang, J.-C.
Affiliations
  • Jinan University (CN)
  • Central South University (CN)
  • Chiba University (JP)
Corresponding author
  • Qi, Qi
  • Hashimoto, Kenji
  • Zhang, Ji-chun
Venue
Molecular Psychiatry
Published
2021-11-24
Volume
27
Issue
3
Pages
1618-1629
ISSN
  • 1359-4184 (ISSN-L)
  • 1476-5578
OpenAlex
W3216353063
Cited by
216
References
80
Citations by year
2026: 29 · 2025: 44 · 2024: 56 · 2023: 50 · 2022: 36 · 2021: 1
FWCI
18.94
Type
journal article
Language
en
Open access
Licence
Locations
  • Molecular Psychiatry (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • MEXT | Japan Society for the Promotion of Science (21H02846, 24116006)
  • National Natural Science Foundation of China (81973341)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
Keywords
(R)-ketamine, antidepressant effects, microglia, ERK signaling, NRBP1, CREB, brain-derived neurotrophic factor, chronic social defeat stress, depression, medial prefrontal cortex, MeCP2, microglial depletion, dendritic spine density, enantiomers, rapid-acting antidepressants
MeSH terms
Animals, Antidepressive Agents, Depression, Humans, Ketamine, Mice, Inbred C57BL, Stress, Psychological, Microglia, Receptors, Cytoplasmic and Nuclear, Brain-Derived Neurotrophic Factor, Vesicular Transport Proteins, Extracellular Signal-Regulated MAP Kinases, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Microglial ERK-NRBP1-CREB-BDNF signaling in sustained antidepressant actions of (R)-ketamine. https://app.cochat.ai/papers/10.1038/s41380-021-01377-7
The paper
Yao, W., Cao, Q., Luo, S., He, L., Yang, C., Chen, J., Qi, Q., Hashimoto, K., & Zhang, J.-C. (2022). Microglial ERK-NRBP1-CREB-BDNF signaling in sustained antidepressant actions of (R)-ketamine. Molecular Psychiatry. https://doi.org/10.1038/s41380-021-01377-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.